another new "glitazone" for type 2 diabetes, Actos (pioglitazone)

You'll soon see another new "glitazone" for type 2 diabetes, Actos (pioglitazone)...co-marketed by Lilly and Takeda.

This is the third one...after Avandia (rosiglitazone) and Rezulin (troglitazone).

All three lower blood glucose by improving insulin sensitivity.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote